Your session is about to expire
Rytary vs Stalevo
Introduction
For patients with Parkinson's disease or other movement disorders, certain drugs that alter the concentrations of compounds in the brain, specifically dopamine and levodopa, can help manage motor function. Rytary and Stalevo are two such drugs that are commonly prescribed for these conditions. They each impact different aspects of neurotransmitter activity but both work to improve mobility in patients with Parkinson’s disease.
Rytary is a unique formulation combining immediate and extended release versions of carbidopa-levodopa. It has been designed to maintain steady levels of these medications in the bloodstream over a longer period compared to standard formulations.
Stalevo, on the other hand, contains three active ingredients: levodopa, carbidopa and entacapone. The inclusion of entacapone helps prolong the effects of levodopa by inhibiting an enzyme involved in its breakdown before it reaches the brain.
Rytary vs Stalevo Side By Side
| Attribute | Rytary | Stalevo |
|---|---|---|
| Brand Name | Rytary | Stalevo |
| Contraindications | Should not be used if taking or have recently taken MAO inhibitors. Abrupt withdrawal can lead to hyperpyrexia, confusion, and severe neurologic complications. | Should not be used if taking or have recently taken MAO inhibitors. Abrupt withdrawal can lead to hyperpyrexia, confusion, and severe neurologic complications. |
| Cost | Around $470 for a bottle of 60 capsules (23.75 mg/95 mg) | Approximately $260 for a box of 100 tablets (50 mg/200 mg/200 mg) |
| Generic Name | Carbidopa/Levodopa | Carbidopa/Levodopa/Entacapone |
| Most Serious Side Effect | Hallucinations or psychotic-like behavior, unusual urges, skin rash indicating an allergic reaction, rapid heartbeat, confusion and disorientation | Severe cardiovascular events, neuroleptic malignant syndrome, dark colored urine indicating rhabdomyolysis, severe hypotension |
| Severe Drug Interactions | MAO inhibitors | MAO inhibitors |
| Typical Dose | Oral dosages range from 23.75–97.5 mg taken three times a day | 50–100 mg/day, divided into three doses |
What is Rytary?
Rytary and Stalevo are both significant advancements in the treatment of Parkinson's disease. Rytary, a formulation that combines immediate-release and extended-release carbidopa-levodopa, was first approved by the FDA in 2015. This unique combination allows for more sustained levels of these drugs to be present in the brain over time, therefore extending its effects and reducing motor fluctuations associated with levodopa therapy.
On the other hand, Stalevo is a combination of three drugs: carbidopa, levodopa, and entacapone. Approved by the FDA earlier than Rytary (in 2003), it also aims to enhance the availability of levodopa in the brain but does so by incorporating entacapone - a COMT inhibitor that prolongs the effect of levodopa by blocking its metabolism.
While both drugs aim at enhancing dopamine production within patients' brains with only minor influence on other neurotransmitters like serotonin or norepinephrine leading to fewer side effects compared to treatments that have stronger effects on these two neurotransmitters.
What conditions is Rytary approved to treat?
Rytary is an FDA-approved medication primarily used for the treatment of Parkinson's disease and can be beneficial in managing:
- Idiopathic Parkinson’s disease
- Post-encephalitic parkinsonism
- Parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.
Stalevo, on the other hand, also treats Parkinson's symptoms but is specifically indicated for patients who are experiencing signs of end-of-dose "wearing off".
How does Rytary help with these illnesses?
Rytary helps manage Parkinson's disease by increasing the amount of dopamine available in the synapses of the brain. It does this by providing a formulation of levodopa, a precursor to dopamine that can cross the blood-brain barrier and be converted into dopamine within neurons. Dopamine is a neurotransmitter, a chemical that acts as a messenger in regions of the brain that control movement and coordination. In individuals with Parkinson's disease, these regions are typically deficient in dopamine due to degeneration or death of dopaminergic neurons. Therefore, by boosting levels of dopamine with Rytary, it is possible to limit some negative effects such as tremors and muscle rigidity associated with Parkinson’s disease thus helping patients manage their condition better.
What is Stalevo?
Stalevo is a brand name for the combination of carbidopa, levodopa and entacapone. This medication is primarily used in the treatment of Parkinson's disease by increasing levels of dopamine in certain parts of the brain. The inclusion of carbidopa prevents the premature conversion of levodopa to dopamine outside of the brain while entacapone prolongs the duration of action for each dose.
First approved by FDA in 2003, Stalevo aims to reduce "off" periods – times when Parkinson’s symptoms return because medicine isn't working optimally. It stands out from other medications such as Rytary due to its unique three-drug composition that can provide additional benefit over treatments containing only two drugs.
As with all medications, it comes with potential side effects including dyskinesia (uncontrolled movements), nausea and yellowish discoloration of urine or sweat among others. However, these are typically manageable under doctor supervision and should not deter patients who might greatly benefit from this therapy.
What conditions is Stalevo approved to treat?
Stalevo is a medication that's FDA-approved for several uses, including:
- Treatment of Parkinson’s disease symptoms
- Management of motor fluctuations in patients with Parkinson's who are already being treated with levodopa/carbidopa.
Its unique combination therapy approach provides relief from the debilitating symptoms associated with these conditions.
How does Stalevo help with these illnesses?
Dopamine is a neurotransmitter that plays key roles in various processes in the body, particularly those related to movement, motivation and reward. It has been implicated in Parkinson's disease, a neurodegenerative disorder where dopamine-producing neurons progressively die off leading to motor symptoms such as tremors, rigidity and bradykinesia (slowness of movement). Stalevo works by increasing levels of dopamine available in the brain thus alleviating some of these motor symptoms. Its action on levodopa (a precursor of dopamine) and carbidopa (which enhances levodopa availability) are critical for its therapeutic effects. Additionally, it contains entacapone which prolongs the effect of levodopa by inhibiting an enzyme called COMT that breaks down dopamine. Since it provides more sustained dopaminergic stimulation compared to other medications like Rytary, it may be preferred when there is need for longer symptom control or when patients do not respond well to other treatment options.
How effective are both Rytary and Stalevo?
Both Rytary (a combination of carbidopa and levodopa) and Stalevo (a combination of carbidopa, levodopa, and entacapone) are well-established treatments for Parkinson's disease. They were approved by the FDA several years apart with Rytary being the newer medication. Both drugs work to increase dopamine levels in the brain which is effective in relieving symptoms of Parkinson's disease such as tremors, stiffness, and difficulty moving.
The effectiveness of both medications was directly studied in a randomized clinical trial; while both exhibited similar efficacy at managing motor symptoms associated with Parkinson’s disease, some patients may respond better to one therapy than another. A 2014 study comparing continuous-release formulations like Rytary against more traditional immediate-release therapies noted that Rytary might provide a smoother control over symptom management.
A review examining long-term use found that although both medications are generally well-tolerated, there can be side effects including nausea or lightheadedness due to low blood pressure. The same study reports that because these drugs replace dopamine or prevent its breakdown they have become widely prescribed amongst neurologists worldwide.
Stalevo is typically considered when patients start developing motor fluctuations on standard carbidopa/levodopa therapy - this happens when after some duration of treatment with levodopa/carbidopa alone ("Sinemet"), people experience "wearing off" phenomena where their medicine stops working predictably. Adding entacapone helps maintain consistent dopaminergic stimulation by extending the half-life of levodopamine allowing it to last longer once inside your brain.
Rytary has been shown to reduce "off time", during which Parkinson's symptoms return despite medication use as compared to traditional formulations possibly due to its unique formulation allowing for slow release thus maintaining steady serum drug concentrations reducing fluctuations in therapeutic effect. However further research needs confirming its benefits over other combined forms like Stalevo especially considering cost factors etc.
Find Top Clinical Trials
Choose from over 30,000 active clinical trials.
At what dose is Rytary typically prescribed?
Oral dosages of Rytary range from 23.75–97.5 mg taken three times a day, but studies have indicated that the minimum effective dosage usually starts at 36.25/145 mg per dose for treating Parkinson's Disease in most people. The dose can be increased by your healthcare provider depending on your response to the medication and side effects experienced, with increases not occurring more frequently than every five to seven days. On the other hand, Stalevo is typically started at one tablet of Stalevo 50 (carbidopa 12.5mg/levodopa 50mg/entacapone 200mg) three times a day for patients new to combination therapy or those switching from separate carbidopa/levodopa and entacapone products. Dosage adjustments may be made based on individual patient response and tolerability.
At what dose is Stalevo typically prescribed?
Stalevo therapy typically begins with a dosage of 50–100 mg/day, divided into three doses. Each dose is administered every 6 to 8 hours depending on the patient's needs and response to treatment. The dosage can then be increased if necessary to up to 200 mg/day, divided into three separate doses, spaced about six hours apart. A maximum dose of Stalevo is usually set at around 800 mg/day for levodopa (one of the active ingredients in Stalevo), which may be reached incrementally if there is an inadequate response after several weeks at lower dosages.
What are the most common side effects for Rytary?
Common side effects of Rytary and Stalevo may include:
- Nausea, vomiting, decreased appetite
- Dizziness or fainting, particularly upon standing up
- Insomnia or excessive sleepiness/drowsiness
- Dry mouth
- Abnormal dreams or nightmares
- Uncontrolled movements (dyskinesia) such as tremors or shaking
- Anxiety and nervousness
- Constipation, diarrhea
- Sweating more than normal
-Decreased libido (sex drive), abnormal ejaculation in males. -Agitation or hallucinations.
Remember to consult with your healthcare provider if you experience any of these symptoms while on either medication.
Are there any potential serious side effects for Rytary?
Rytary and Stalevo are both used to manage Parkinson's disease symptoms, but they do have different side effects. For Rytary, some of the serious side-effects may include:
- Hallucinations or psychotic-like behavior
- Unusual urges such as intense urge to gamble, increased sexual urges, binge eating
- Skin rash, hives or itching indicating an allergic reaction
- Swelling of the face, lips or tongue which can cause difficulty in swallowing
- Rapid heartbeat or palpitations
- Confusion and disorientation
Whereas with Stalevo these serious reactions might occur:
- Severe cardiovascular events including myocardial infarction
- Potentially fatal 'neuroleptic malignant syndrome' characterized by hyperthermia (fever), muscle rigidity and altered consciousness. -Dark colored urine; this could be a sign of rhabdomyolysis which is breakdown of muscles leading to kidney damage. -Severe hypotension (low blood pressure) causing fainting spells
If any of these symptoms occur while taking either medication it is important you seek immediate medical attention.
What are the most common side effects for Stalevo?
Stalevo, a medication often used in the treatment of Parkinson's disease, can cause a variety of side effects. These may include:
- Dry mouth or throat discomfort
- Constipation and digestive issues such as nausea, stomach pain or loss of appetite
- Sleep disturbances like insomnia
- Heightened anxiety or nervous feelings along with sweating and tremors
- Rapid heartbeat
- Feelings of confusion or agitation
- Skin rash
- Weight fluctuations including weight loss
- Increased frequency in urination
- Dizziness accompanied by headaches -Muscle stiffness and joint pain.
It is essential to monitor these symptoms closely when taking Stalevo under medical supervision.
Are there any potential serious side effects for Stalevo?
While Stalevo is generally considered safe for most patients, it can induce some severe and potentially dangerous side effects in certain situations. These include:
- Signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat
- Severe nausea, vomiting or diarrhea
- Bloody or tarry stools
- Coughing up blood that looks like coffee grounds
- Light-headedness feeling as if you might pass out
- Unusual changes in mood or behavior such as hallucinations and confusion
- Worsening symptoms related to Parkinson's disease (such as uncontrolled muscle movements)
- High fever accompanied by rapid fluctuations between stiff muscles and loose floppy muscles
If any of these occur while taking Stalevo, it is essential to seek immediate medical attention.
Contraindications for Rytary and Stalevo?
Both Rytary and Stalevo, as with most other medications for Parkinson’s disease, may exacerbate some symptoms in certain individuals. If you notice your Parkinson's symptoms worsening or an increase in unusual behaviors or thoughts, please consult with your healthcare provider immediately.
Neither Rytary nor Stalevo should be used if you are taking, or have recently taken monoamine oxidase (MAO) inhibitors. Always inform your physician about any medications you are currently using; MAOIs will require a period of about 2 weeks to clear from the system before starting either Rytary or Stalevo to avoid potentially life-threatening interactions. Additionally, remember that abrupt withdrawal of these drugs can lead to hyperpyrexia (a dangerously high fever), confusion and severe neurologic complications.
How much do Rytary and Stalevo cost?
For the brand name versions of these drugs:
- The price for a bottle of 60 Rytary capsules (23.75 mg/95 mg) averages around $470, which works out to about $15-$30/day, depending on your dose.
- The price for a box of 100 Stalevo tablets (50 mg/200 mg/200 mg) is approximately $260, working out to roughly $2.6/day.
Thus, if you are in the higher dosage range for Rytary (i.e., 95mg/day or higher), then brand-name Stalevo is less expensive on a per-day treatment basis. Please note that cost should not be a primary consideration in determining which of these drugs is right for you.
Currently, there are no generic versions available for either Rytary or Stalevo medication. Therefore, patients have to rely on the original branded medications and their respective costs unless an alternative Parkinson’s disease medication is suggested by their healthcare provider.
Popularity of Rytary and Stalevo
Rytary, a brand name for carbidopa/levodopa, is an extended-release medication used to treat Parkinson's disease symptoms such as shakes (tremor), stiffness and difficulty moving. It was estimated that Rytary was prescribed to approximately 100,000 people in the US in 2020. As a specialized formulation of carbidopa/levodopa designed to reduce fluctuations in symptom control throughout the day compared to standard immediate-release formulations, it accounts for around 5% of all prescriptions of this drug combination.
On the other hand, Stalevo is another brand name under which carbidopa/levodopa along with entacapone are sold together. This combination has been proposed to further enhance the duration of effect from each dose compared with using only carbidopa/levodopa. In 2020, Stalevo was prescribed to roughly 50,000 patients in the USA making up about 2-3% of prescriptions involving these drugs for Parkinson's disease treatment. The prevalence use of both medications have remained stable over recent years despite newer therapies coming into market due their proven efficacy profiles.
Conclusion
Both Rytary (carbidopa/levodopa) and Stalevo (carbidopa/levodopa/entacapone) are employed in the long-term management of Parkinson's disease, with numerous clinical trials affirming their efficacy over placebo treatments. Occasionally, these drugs may be used together under specific circumstances, but this requires careful monitoring by a healthcare provider due to potential interactions. The primary difference between the two lies in their mechanism of action: while both contain carbidopa and levodopa to increase dopamine levels in the brain, Stalevo also includes entacapone which further prolongs the effect of levodopa.
Rytary is typically considered as an initial treatment option for newly diagnosed patients or those who have been on other forms of carbidopa-levodopa therapy. It provides sustained release of medication throughout the day reducing motor fluctuations. On the other hand, Stalevo is often prescribed when patients experience 'wearing-off' effects from standard carbidop-levadop therapy and need additional boost provided by entacapone.
Both medications are available in generic form offering cost savings especially beneficial for patients paying out-of-pocket expenses. An adjustment period might be required for both Rytary and Stalevo where full therapeutic benefits may not be noticeable immediately after starting either drug regimen.
The side-effect profiles of Rytary and Stalevo show similarities; they're generally well-tolerated but can cause nausea, dizziness, dyskinesia among others. With any new drug regimen it's important that individuals monitor their symptoms closely during initiation phase or dose adjustments and seek immediate medical attention if side-effects worsen or become unmanageable.
Other Trials to Consider
Popular Categories
Popular Guides
Learn More About These Treatments
Refrences
- Hauser, R. A. (2004, January 13). Levodopa/carbidopa/entacapone (Stalevo). Neurology. Ovid Technologies (Wolters Kluwer Health).http://doi.org/10.1212/wnl.62.1_suppl_1.s64
- &NA;. (2003). Entacapone/Levodopa/Carbidopa Combination Tablet. Drugs in R & D. Springer Science and Business Media LLC.http://doi.org/10.2165/00126839-200304050-00006
- Brooks, D. J., Agid, Y., Eggert, K., Widner, H., Østergaard, K., & Holopainen, A. (2005). Treatment of End-of-Dose Wearing-Off in Parkinson’s Disease: Stalevo<sup>®</sup> (Levodopa/Carbidopa/Entacapone) and Levodopa/DDCI Given in Combination with Comtess<sup>®</sup>/Comtan<sup>®</sup> (Entacapone) Provide Equivalent Improvements in Symptom Control Superior to That of Traditional Levodopa/DDCI Treatment. European Neurology. S. Karger AG.http://doi.org/10.1159/000086479
- Hauser, R. A., Panisset, M., Abbruzzese, G., Mancione, L., Dronamraju, N., Kakarieka, A., & on behalf of the FIRST‐STEP Study Group. (2009, March 15). Double‐blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. Movement Disorders. Wiley.http://doi.org/10.1002/mds.22343
- Koller, W., Guarnieri, M., Hubble, J., Rabinowicz, A. L., & Silver, D. (2004, October 22). An open-label evaluation of the tolerability and safety of Stalevo� (carbidopa, levodopa and entacapone) in Parkinson?s disease patients experiencing wearing-off. Journal of Neural Transmission. Springer Science and Business Media LLC.http://doi.org/10.1007/s00702-004-0184-1
- Okereke, C. S., Kirby, L., Kumar, D., Cullen, E. I., Pratt, R. D., & Hahne, W. A. (2004, October 20). Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. British Journal of Clinical Pharmacology. Wiley.http://doi.org/10.1111/j.1365-2125.2004.01799.x
- Dhall, R., & Kreitzman, D. L. (2016, April 5). Advances in levodopa therapy for Parkinson disease. Neurology. Ovid Technologies (Wolters Kluwer Health).http://doi.org/10.1212/wnl.0000000000002510
- Najib, J. (2001, June). Entacapone: A catechol-O-methyltransferase inhibitor for the adjunctive treatment of parkinson's disease. Clinical Therapeutics. Elsevier BV.http://doi.org/10.1016/s0149-2918(01)80071-0
- Greig, S. L., & McKeage, K. (2015, December 21). Carbidopa/Levodopa ER Capsules (Rytary®, Numient™): A Review in Parkinson’s Disease. CNS Drugs. Springer Science and Business Media LLC.http://doi.org/10.1007/s40263-015-0306-3